High-Level Expression Of Recombinant Antibody In A Mammalian Host Cell

Patent No. EP1915394 (titled "High-Level Expression Of Recombinant Antibody In A Mammalian Host Cell") was filed by Lonza Biologics on May 19, 2006. The application was issued on Jan 27, 2021.

Patent Summary

A mammalian expression vector for Chinese Hamster Ovary (CHO) cells that enables high-level production of recombinant antibodies. The vector contains a double-gene construct with gene-optimized nucleotide sequences for both the light and heavy chains of an antibody, where the codon composition is tailored to the codon bias of CHO cells. This optimized vector significantly enhances antibody production compared to conventional vectors, achieving a median level of 51.3 µg/ml. The gene optimization does not alter the amino acid sequences of the antibody chains, but rather optimizes transcriptional efficiency and mRNA stability through removal of cis-acting sequence motifs.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP1915394

LONZA BIOLOGICS
Application Number
EP06753745A
Filing Date
May 19, 2006
Status
Revoked
Mar 22, 2024
Publication Date
Jan 27, 2021